J Drugs Dermatol. 2021 Apr 1;20(4):380-383. doi: 10.36849/JDD.2021.5673.
Melanoma is a common tumor accounting for around 3–5% of all cutaneous malignancies with worldwide increasing incidence. It is still associated with significant mortality despite the breakthrough of new innovative therapies within the last decade. A wide variety of treatment modalities is currently used for the management of melanoma, ranging from surgical excision of primary melanoma to adju-vant and palliative treatment with target molecules, including BRAF and MEK inhibitors, and immune checkpoint inhibitors. β-blockers have recently demonstrated in preclinical and clinical studies to reduce recurrence and to correlate with better overall survival in meta-static melanoma as an additional supportive treatment option, owing to their anti-tumor potential. Further investigation regarding their efficacy and safety profile is needed, since there are only few studies in the literature on this topic. Our aim is to evaluate the role and current status of β-blockers in melanoma management. The literature research includes peer-reviewed articles (clinical trials or scien-tific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) till May 2020 and reference lists of respective articles. Only articles published in English language were included. J Drugs Dermatol. 20(4):380-383. doi:10.36849/JDD.5673.
黑素瘤是一种常见的肿瘤，占所有皮肤恶性肿瘤的 3%至 5%，全球发病率呈上升趋势。尽管在过去十年中出现了新的创新疗法，但它仍然与显著的死亡率相关。目前有多种治疗方法可用于治疗黑素瘤，从原发性黑素瘤的手术切除到辅助和姑息治疗，包括靶向分子治疗，如 BRAF 和 MEK 抑制剂以及免疫检查点抑制剂。β-受体阻滞剂在临床前和临床研究中最近显示出降低复发率并与转移性黑素瘤的总体生存率相关，作为一种额外的支持性治疗选择，这归因于其抗肿瘤潜力。由于文献中关于该主题的研究较少，因此需要进一步研究其疗效和安全性。我们的目的是评估 β-受体阻滞剂在黑素瘤管理中的作用和现状。文献研究包括同行评议的文章（临床试验或科学综述）。通过搜索电子数据库（MEDLINE 和 PubMed），直到 2020 年 5 月确定了研究，并查阅了相应文章的参考文献列表。仅纳入发表在英语期刊上的文章。J Drugs Dermatol. 20(4):380-383. doi:10.36849/JDD.5673.
